## II. Remarks/Arguments

This Amendment is in response to the Office Action mailed May 17, 2006. Claims 1, 3, 5-10, 17, 19-28 and 30-37 are pending in this case.

Claims 1, 3, 7-10, 17, 19-28, 30, 31 and 36-39 have been rejected under 35 USC 103(a) as being unpatentable over Skee et al (US 5,989,353).

Claim 6 has been rejected under 35 USC 103(a) as being unpatentable over Skee et al (US 5,989,353) as applied to Claims 1, 3, 7-10, 17, 19-28, 30, 31 and 36-39 above, and further in view of Skee (US 2002/0077259).

Claim 5 has been rejected under 35 USC 103(a) as being unpatentable over Skee et al (US 5,989,353) as applied to Claims 1, 3, 7-10, 17, 19-28, 30, 31 and 36-39 above, and further in view of Seijo et al (US 2002/0181342).

Claims 1, 7, 10 and 37 have been rejected under 35 USC 102(b) as being anticipated by EP 020,042.

Claims 1, 8, 10 and 37 have been rejected under 35 USC 102(b) as being anticipated by Yarham et al (US 4,379,072).

Claims 22 and 36 have been rejected under 35 USC 103(a) as being unpatentable over Yarham et al (US 4,379,072).

Claims 1, 7-10, 22, 24, 25, 26 and 32-37 have been provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over Claims 1-17 and 22-29 of copending Application No. 10/832,139 in view of EP 020042.

As indicated on page 1 of the Final Office Action mailed May 17, 2006, Claims 32-35 have been objected to. As previously indicated in the Office Action mailed October 20, 2005, Claims 32-35 were objected to but were found to contain allowable subject matter.

In view the same, independent Claims 1, 17, 22, 27, 36 and 37 have been amended to incorporate the allowable subject matter of Claim 32, which as a result has been canceled. Dependent Claims 3, 5-10, 19-21, 28, 31, 34 and 35 have been amended accordingly. Similarly, allowable Claim 33 has been rewritten in independent form. Dependent Claims 23-26, 30 and 38-39 remain unchanged. New Claims 40 and 41 have been added.

While it is believed that the prior art rejections are inapplicable in view of the above amendments, the rejections are nonetheless traversed as follows.

Skee et al., Skee and Seijo et al. do not relate to corrosion inhibiting, but instead relate to cleaning solutions for cleaning metal contamination from microelectronic wafer substrate surfaces. The wafer surface is being cleaned, not corrosion inhibited (as such wafers do not corrode).

With respect to EP 0020042 and Yarham et al., as previously indicated, Applicant's amine complexing agent is an alkylamine, and preferably is selected from the group consisting of 3-methoxypropylamine, 4-ethylmorpholine. dimethylaminopropylamine and aminopropylmorpholine. It is respectfully submitted that none of the cited prior art discloses, teaches or suggests the claimed use of an alkylamine, nor one selected from the group consisting 3-methoxypropylamine, 4-ethylmorpholine, of dimethylaminopropylamine and aminopropylmorpholine. To the contrary, the cited prior art references disclose different uses of an alkanolamine. Alkanolamines are organic nitrogen compounds containing an -OH group. These substances must contain "-nol" in their nomenclature, e.g., monoethanolamine, diethanolamine, triethanolamine, aminoethylethanolamine. Alkylamines, on the other hand, are simply amines formed when an alkyl group (e.g. methyl, propyl, ethyl) is attached to the nitrogen of an amine, e.g., ethylamine, propylamine, dimethylaminopropylamine. In view of the same,

New Claim 41 sets forth the negative limitation that the chemical composition (in Claim 1) does not include an alkanolamine.

It is respectfully submitted that none of the prior art of record, either alone or in combination, fairly teaches, suggests or discloses the novel and unobvious features of Applicant's amended claims as set forth above. Accordingly, Applicant respectfully asserts that the claims as presented herein are now in condition for allowance. An early notice allowance is respectfully requested.

Claims 1, 7-10, 22, 24, 25, 26 and 32-37 have been provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over Claims 1-17 and 22-29 of copending Application No. 10/832,139 in view of EP 020042. For the following reasons, the double patenting rejection is respectfully traversed.

Claims 1-17 and 22-29 of copending Application No. 10/832,139 recite a hydrotalcite or a hydrotalcite-like material, while the claims set forth herein do not. Further, the claims set forth herein recite an alkylamine or specific alkylamines, while Claims 1-17 and 22-29 of copending Application No. 10/832,139 do not. As such, the respective claims are patentable distinct from each other, especially in view of the amendments herein. Thus, Applicant respectfully requests that the provisional double patenting rejection be withdrawn.

Any arguments of the Examiner not specifically addressed should not be deemed admitted, conceded, waived, or acquiesced by Applicant. Any additional or outstanding matters the Examiner may have are respectfully requested to be disposed of by telephoning the undersigned.

A Request for Continued Examination (RCE) is enclosed herewith.

A Petition for Extension of Time necessary to make this response timely is enclosed herewith.

A form PTO-2038 authorizing a credit card charge of the required extension fee and for the RCE fee is enclosed. The Commissioner is hereby authorized to charge any deficient fees or any additional fees which may be required to Deposit Account No. 16-0657, including any additional claims fees if exceeding the fees previously paid.

A postcard is enclosed evidencing receipt of the same.

Respectfully submitted,

PATULA & ASSOCIATES, P.C.

autint

Charles T. Riggs Jr. Reg. No. 37,430

Attorney for Applicant

PATULA & ASSOCIATES, P.C. 116 S. Michigan Avenue, 14th Floor Chicago, Illinois 60603 (312) 201-8220

67C44